---
figid: PMC4539082__dddt-9-4479Fig2
figtitle: Clinical development of galunisertib (LY2157299 monohydrate), a small molecule
  inhibitor of transforming growth factor-beta signaling pathway
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC4539082
filename: dddt-9-4479Fig2.jpg
figlink: /pmc/articles/PMC4539082/figure/f2-dddt-9-4479/
number: F2
caption: 'TGF-βRI (ALK5) and TGF-βRII canonical activation.Note: Galunisertib blocks
  the kinase of the ALK5 pathway reducing the pSMAD2 activation in cells.Abbreviations:
  ALK5, activin receptor-like kinase 5; pSMAD2, phosphorylation of SMAD2; TGF-β, transforming
  growth factor-beta.'
papertitle: Clinical development of galunisertib (LY2157299 monohydrate), a small
  molecule inhibitor of transforming growth factor-beta signaling pathway.
reftext: Stephan Herbertz, et al. Drug Des Devel Ther. 2015;9:4479-4499.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8007875
figid_alias: PMC4539082__F2
figtype: Figure
redirect_from: /figures/PMC4539082__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4539082__dddt-9-4479Fig2.html
  '@type': Dataset
  description: 'TGF-βRI (ALK5) and TGF-βRII canonical activation.Note: Galunisertib
    blocks the kinase of the ALK5 pathway reducing the pSMAD2 activation in cells.Abbreviations:
    ALK5, activin receptor-like kinase 5; pSMAD2, phosphorylation of SMAD2; TGF-β,
    transforming growth factor-beta.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TGFBR1
  - SMAD3
  - SMAD2
  - SMAD4
---
